NASDAQ: WGSGenedx Holdings Corp Stock
$1.50-0.10 (-6.25%)
Updated Dec 7, 2023
WGS Price
$1.50
Fair Value Price
$4.07
Market Cap
$38.83M
52 Week Low
$1.16
52 Week High
$17.91
P/E
-0.04x
P/B
0.15x
P/S
0.46x
PEG
N/A
Dividend Yield
N/A
Revenue
$206.50M
Earnings
-$458.76M
Gross Margin
20.8%
Operating Margin
-221.81%
Profit Margin
-222.2%
Debt to Equity
0.64
Operating Cash Flow
-$215M
Beta
1.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
WGS Overview
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how WGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WGS ($1.50) is undervalued by 63.18% relative to our estimate of its Fair Value price of $4.07 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
WGS ($1.50) is significantly undervalued by 63.18% relative to our estimate of its Fair Value price of $4.07 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
WGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more WGS due diligence checks available for Premium users.
Be the first to know about important WGS news, forecast changes, insider trades & much more!
WGS News
Valuation
WGS fair value
Fair Value of WGS stock based on Discounted Cash Flow (DCF)
Price
$1.50
Fair Value
$4.07
Undervalued by
63.18%
WGS ($1.50) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
WGS ($1.50) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
WGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
WGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
23.72x
Market
31.17x
WGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.15x
Industry
2.99x
WGS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WGS's financial health
Profit margin
Revenue
$53.3M
Net Income
-$42.3M
Profit Margin
-79.3%
WGS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
WGS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$417.3M
Liabilities
$163.0M
Debt to equity
0.64
WGS's short-term assets ($171.81M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WGS's short-term assets ($171.81M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$41.2M
Investing
-$27.1M
Financing
-$911.0k
WGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WGS vs Health Information Service Stocks
Genedx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.